<code id='34CEAEE453'></code><style id='34CEAEE453'></style>
    • <acronym id='34CEAEE453'></acronym>
      <center id='34CEAEE453'><center id='34CEAEE453'><tfoot id='34CEAEE453'></tfoot></center><abbr id='34CEAEE453'><dir id='34CEAEE453'><tfoot id='34CEAEE453'></tfoot><noframes id='34CEAEE453'>

    • <optgroup id='34CEAEE453'><strike id='34CEAEE453'><sup id='34CEAEE453'></sup></strike><code id='34CEAEE453'></code></optgroup>
        1. <b id='34CEAEE453'><label id='34CEAEE453'><select id='34CEAEE453'><dt id='34CEAEE453'><span id='34CEAEE453'></span></dt></select></label></b><u id='34CEAEE453'></u>
          <i id='34CEAEE453'><strike id='34CEAEE453'><tt id='34CEAEE453'><pre id='34CEAEE453'></pre></tt></strike></i>

          Home / entertainment / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:4868
          Powdered ibogaine against a white background.
          Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

          The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

          The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

          advertisement

          But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In